top of page

Biotech entrepreneurs share advice on navigating through today's uncertain times: "It's going to be okay" | 10/22/25

TOP VIDEO: Biotech entrepreneurs share advice on navigating through today's uncertain times: "It's going to be okay" | 10/22/25

Quick Takes

Upcoming Events

October 7 - Align Summit | Boston, MA

November 3-5 - BIO-Europe 2025 | Vienna, Austria

November 7-9 - SITC Annual Meeting | National Harbour, MD

November 11-12 - Stifel Healthcare Conference | New York, NY

December 5-9 - ASH Annual Meeting | Orlando, FL

Science Spotlight
with Chloe Kirk

10/10/25 - OrganOx illustrates how to keep organs alive outside of the body longer for use in transplants with its 'metra device'.

10/10/25 - A scientist at OMass Therapeutics in Oxford, UK shows BiotechTV some of the company's mass spectrometry equipment.

10/9/25 - A scientist at OMass Therapeutics in Oxford, UK explains how to prep proteins for analysis with mass spectrometry.

Latest Videos

Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry | 10/22/25

Company News:

Flagship Pioneering announced Expedition Medicines today. It is leveraging generative design for small molecule covalent chemistry

10/22/2025

State of the U.S. Life Sciences Market

Savills Life Sciences:
Report - U.S. Life Sciences State of the Market 2025

Download the Report

Sponsored

Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity | 10/21/25

Company News:

Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the company's science

10/21/2025

Get to know Women In Bio, and how this organization helps women at all stages of their careers in biotech | 10/21/25

Bright Minds:

Get to know Women In Bio, and how this organization helps women at all stages of their careers in biotech

10/21/2025

BioVenture VoiCes Episode 27: Avalon Bioventures' Jay Lichter | 10/20/25

BioVenture VoiCes:

Jay Lichter recounts the numerous companies he has either operated or funded in his career, leading to his work today at Avalon Bioventures

10/20//2025

Shows

Around Kendall Square

What's new at BiotechTV - from our founder

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

09:50

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

12:06

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

11:05

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

09:45

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

11:42

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

19:05

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

12:13

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

15:58

2025 SF Healthcare Week

ASCO25: Gilead Sciences Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more in the oncology pipeline | 05/31/25

15:21

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor | 06/01/25

09:08

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25

19:01

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news | 05/30/25

09:58

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline | 05/31/25

08:29

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation | 06/01/25

11:26

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer | 06/01/25

11:00

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors | 06/01/25

12:14

#ASCO25

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

14:22

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

13:56

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

13:29

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

12:34

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

09:41

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

14:12

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

11:37

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

06:43

#ASH24

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Learn more about Klein Hersh

bottom of page